Aktiesnakken — Oktober 2009
-
kommende indikationer vil kræve væsentlig mindre doser
-
Wouvser er dobbelt så godt som analytikerne har forventet
-
var det $27-36.000 per behandling for andre indikationer?
-
Jeg mener konsensus ligger på 44k
-
ja..... 6300-8300 mg....
-
Det er første gang vi hører om pris fra Genmab/gsk
-
"the patients have obviously lived longer than we had expected"..... vedr. efgr først i 2010...
-
forventer egfr data i Q1
-
Det er faneme i orden....kom nu!!!
-
emissionsspgm fra frank, jyske bank...
-
kap udv?
-
very careful about our spending plan
-
strengt... i er foran mig.
-
newer say newer, but no plans about
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind